Real-world evaluation of quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer: the prospective QoLiTrap study
Aflibercept plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer after the failure of oxaliplatin-containing therapy. QoLiTrap prospectively evaluated the quality of life (QoL) and effectiveness of this regimen in daily clinical practice, according to RAS status,...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
20 July 2022
|
| In: |
Cancers
Year: 2022, Jahrgang: 14, Heft: 14, Pages: 1-14 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers14143522 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/cancers14143522 Verlag, kostenfrei, Volltext: https://www.mdpi.com/2072-6694/14/14/3522 
|
| Verfasserangaben: | Ralf-Dieter Hofheinz, Sandro Anchisi, Birgit Grünberger, Hans G. Derigs, Mark-Oliver Zahn, Christine Geffriaud-Ricouard, Max Gueldner, Christine Windemuth-Kieselbach, Stefanie Pederiva, Pierre Bohanes, Felicitas Scholten, Gudrun Piringer, Josef Thaler and Roger von Moos |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1871446007 | ||
| 003 | DE-627 | ||
| 005 | 20240307081422.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231128s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers14143522 |2 doi | |
| 035 | |a (DE-627)1871446007 | ||
| 035 | |a (DE-599)KXP1871446007 | ||
| 035 | |a (OCoLC)1425216353 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 245 | 1 | 0 | |a Real-world evaluation of quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer |b the prospective QoLiTrap study |c Ralf-Dieter Hofheinz, Sandro Anchisi, Birgit Grünberger, Hans G. Derigs, Mark-Oliver Zahn, Christine Geffriaud-Ricouard, Max Gueldner, Christine Windemuth-Kieselbach, Stefanie Pederiva, Pierre Bohanes, Felicitas Scholten, Gudrun Piringer, Josef Thaler and Roger von Moos |
| 264 | 1 | |c 20 July 2022 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.11.2023 | ||
| 520 | |a Aflibercept plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer after the failure of oxaliplatin-containing therapy. QoLiTrap prospectively evaluated the quality of life (QoL) and effectiveness of this regimen in daily clinical practice, according to RAS status, sex, and prior targeted therapy, especially epidermal growth factor receptor inhibitors (EGFR-I). The primary endpoint was the percentage of patients whose EORTC QLQ-C30 global health status (GHS) improved or reduced by <5% from baseline during the first 12 weeks of therapy. Secondary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. One thousand two hundred and seventy-seven patients were treated with aflibercept plus FOLFIRI and 872 were evaluable for QoL. GHS improved or decreased by <5% in 40.3% of cases. The ORR was 20.8%, the median PFS was 7.8 months (95% confidence interval (CI), 7.3-8.3), and the median OS was 14.4 months (95% CI, 13.1-18.1). After prior EGFR-I, the ORR was 23.7%, median PFS was 9.4 months (95% CI, 6.5-12.9), and median OS was 17.4 months (95% CI, 10.5-33.7). The safety profile was consistent with previously reported data. Aflibercept plus FOLFIRI given in daily practice maintained QoL in mCRC patients, was associated with a high objective tumor response, and retained its activity regardless of sex, RAS status, and prior EGFR-I therapy. | ||
| 650 | 4 | |a aflibercept | |
| 650 | 4 | |a anti-angiogenics | |
| 650 | 4 | |a colorectal cancer | |
| 650 | 4 | |a EGFR inhibitors | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a VEGF | |
| 700 | 1 | |a Anchisi, Sandro |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grünberger, Birgit |e VerfasserIn |4 aut | |
| 700 | 1 | |a Derigs, Hans G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zahn, Mark-Oliver |e VerfasserIn |4 aut | |
| 700 | 1 | |a Geffriaud-Ricouard, Christine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gueldner, Max |e VerfasserIn |4 aut | |
| 700 | 1 | |a Windemuth-Kieselbach, Christine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pederiva, Stefanie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bohanes, Pierre |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scholten, Felicitas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Piringer, Gudrun |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thaler, Josef |e VerfasserIn |4 aut | |
| 700 | 1 | |a von Moos, Roger |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 14(2022), 14, Artikel-ID 3522, Seite 1-14 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a Real-world evaluation of quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer the prospective QoLiTrap study |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:14 |g elocationid:3522 |g pages:1-14 |g extent:14 |a Real-world evaluation of quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer the prospective QoLiTrap study |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers14143522 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/14/14/3522 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20231128 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j | ||
| 999 | |a KXP-PPN1871446007 |e 4419228962 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Real-world evaluation of quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer","subtitle":"the prospective QoLiTrap study","title":"Real-world evaluation of quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer"}],"language":["eng"],"physDesc":[{"extent":"14 S."}],"id":{"doi":["10.3390/cancers14143522"],"eki":["1871446007"]},"note":["Gesehen am 28.11.2023"],"relHost":[{"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedKey":"2009","dateIssuedDisp":"2009-","publisher":"MDPI","publisherPlace":"Basel"}],"recId":"614095670","note":["Gesehen am 27.05.2020"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Real-world evaluation of quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer the prospective QoLiTrap studyCancers","id":{"eki":["614095670"],"issn":["2072-6694"],"zdb":["2527080-1"]},"language":["eng"],"part":{"text":"14(2022), 14, Artikel-ID 3522, Seite 1-14","year":"2022","volume":"14","pages":"1-14","extent":"14","issue":"14"},"title":[{"title":"Cancers","title_sort":"Cancers"}],"pubHistory":["1.2009 -"]}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"20 July 2022"}],"recId":"1871446007","person":[{"family":"Hofheinz","display":"Hofheinz, Ralf-Dieter","given":"Ralf-Dieter","role":"aut"},{"role":"aut","given":"Sandro","display":"Anchisi, Sandro","family":"Anchisi"},{"family":"Grünberger","display":"Grünberger, Birgit","given":"Birgit","role":"aut"},{"family":"Derigs","display":"Derigs, Hans G.","given":"Hans G.","role":"aut"},{"family":"Zahn","display":"Zahn, Mark-Oliver","given":"Mark-Oliver","role":"aut"},{"family":"Geffriaud-Ricouard","given":"Christine","role":"aut","display":"Geffriaud-Ricouard, Christine"},{"family":"Gueldner","display":"Gueldner, Max","given":"Max","role":"aut"},{"family":"Windemuth-Kieselbach","display":"Windemuth-Kieselbach, Christine","role":"aut","given":"Christine"},{"family":"Pederiva","display":"Pederiva, Stefanie","given":"Stefanie","role":"aut"},{"family":"Bohanes","display":"Bohanes, Pierre","given":"Pierre","role":"aut"},{"family":"Scholten","display":"Scholten, Felicitas","role":"aut","given":"Felicitas"},{"family":"Piringer","display":"Piringer, Gudrun","given":"Gudrun","role":"aut"},{"display":"Thaler, Josef","given":"Josef","role":"aut","family":"Thaler"},{"display":"von Moos, Roger","given":"Roger","role":"aut","family":"von Moos"}],"name":{"displayForm":["Ralf-Dieter Hofheinz, Sandro Anchisi, Birgit Grünberger, Hans G. Derigs, Mark-Oliver Zahn, Christine Geffriaud-Ricouard, Max Gueldner, Christine Windemuth-Kieselbach, Stefanie Pederiva, Pierre Bohanes, Felicitas Scholten, Gudrun Piringer, Josef Thaler and Roger von Moos"]}} | ||
| SRT | |a HOFHEINZRAREALWORLDE2020 | ||